Results 141 to 150 of about 3,726 (180)
Some of the next articles are maybe not open access.
Guselkumab in Behçet's disease
Annals of the Rheumatic DiseasesN ...
Elie E Ghayad +14 more
openaire +3 more sources
Canadian Journal of Health Technologies, 2022
CADTH recommends that Tremfya be reimbursed by public drug plans for the treatment of active psoriatic arthritis (PsA) if certain conditions are met. Tremfya should only be reimbursed to treat adult patients with active PsA according to the reimbursement criteria used for other biologic disease-modifying antirheumatic drugs (DMARDs) that ...
openaire +1 more source
CADTH recommends that Tremfya be reimbursed by public drug plans for the treatment of active psoriatic arthritis (PsA) if certain conditions are met. Tremfya should only be reimbursed to treat adult patients with active PsA according to the reimbursement criteria used for other biologic disease-modifying antirheumatic drugs (DMARDs) that ...
openaire +1 more source
Guselkumab for the treatment of palmoplantar pustulosis
Expert Opinion on Biological Therapy, 2020Palmoplantar pustulosis, or pustulosis palmaris et plantaris (PPP), is a chronic, recurrent inflammatory skin disease that is sometimes unresponsive to conventional therapy. The anti-interleukin 23 antibody guselkumab is effective for treating PPP.This review details the current understanding of PPP and discusses why guselkumab may be effective ...
openaire +2 more sources
Guselkumab: First Global Approval
Drugs, 2017Guselkumab (Tremfya™) is a human monoclonal IgG1λ antibody being developed by Janssen Biotech, Inc. that has been approved in the USA as a treatment for moderate-to-severe plaque psoriasis. Guselkumab inhibits the binding of interleukin 23 (IL-23) to its cell surface receptor, disrupting the type 17 helper T cell/IL-17 pathway.
openaire +2 more sources
Canadian Journal of Health Technologies
Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception ...
openaire +1 more source
Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception ...
openaire +1 more source
Guselkumab for the Treatment of Crohn’s Disease: Induction Results From the Phase 2 GALAXI-1 Study
Gastroenterology, 2022Walter Reinisch +2 more
exaly
Plaatsbepaling guselkumab = Determining the role of guselkumab
Nederlands Tijdschrift voor Dermatologie en Venereologie, 2020van Eijsden, Claire, van Doorn, Martijn
openaire +1 more source